Getinge Announces U.S. Commercial Availability of iCast Covered Stent System for Treatment of Iliac Arterial Occlusive Disease
Today Getinge announced commercial availability of the iCast covered stent system in the United States for the treatment of iliac arterial occlusive disease. In March 2023, the iCast covered stent received premarket approval from the U.S. Food and Drug Administration (FDA) for the treatment of iliac arterial occlusive disease. Lower extremity peripheral artery disease (PAD) is estimated to affect approximately 8.5 million people in the U.S. per year [1],[2].
“We are very pleased that the iCast covered stent is now available to clinicians and hospital systems throughout the U.S. for the treatment of this serious and often painful condition for patients,” said Patricia Fitch, President Getinge, North America. “This indication is another reflection of Getinge’s commitment to bringing our U.S. customers the high-quality products and support they need for their patients.”
To support the commercial availability of the iCast covered stent, Getinge will take part in two upcoming medical meetings:
• Getinge will attend the VIVA (Vascular InterVentional Advances) conference being held October 30-November 1, 2023, at the Wynn Hotel in Las Vegas, Nevada. Attendees will be able to access information about the iCast covered stent at the Getinge booth (#316) during the conference. Getinge will also sponsor a breakout session led by Christopher J. Smolock, MD, Vascular Surgeon at Mount Sinai Queens, titled “Effective Treatment of TASC D Common Iliac Lesions Utilizing the iCast Covered Stent System” during the meeting. Dr. Smolock’s presentation will be held Wednesday, November 1, 2023, from 10:20am-10:45am PST in the Red Theater (Lafite Ballroom).
• Getinge will also attend the VEITH symposium being held November 14-18, 2023, at the Hilton Midtown Hotel in New York, New York. Attendees can access information about the iCast covered stent at the Getinge booth (#513) and also attend a satellite symposium on Thursday, November 16 from 4:00pm to 6:00pm EST.
“iCast, marketed outside the U.S. as Advanta V12, has been used by clinicians for more than 20 years. The use of iCast for the treatment of iliac arterial occlusive disease builds on this strong history of clinical experience and reflects Getinge’s commitment to developing and delivering products that represent the highest standards in safety and performance,” said Therese Mueller, Vice President of Sales, Acute Care Therapies at Getinge. "We are very pleased that the system and the full range of Getinge support materials and services will now be available to support physicians who treat patients affected by this devastating disease."
About Getinge
Getinge is a global provider of innovative solutions for operating rooms, intensive-care units, sterilization departments and for life science companies and institutions. Based on our first-hand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving the everyday life for people, today and tomorrow.
Media contact:
Peter Dannenfelser, Sr. Director Marketing Communications
(973) 629-2192
Peter.Dannenfelser@Getinge.com
Sources
[1] Neisen, M. J. (2009). Endovascular management of aortoiliac occlusive disease. Seminars in Interventional Radiology, 26(4), 296–302. https://doi.org/10.1055/s-0029-1242199
[2] Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FGR, Hamburg NM, Kinlay S, et al. (2017). 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 135, e686–e725. doi: 10.1161/CIR.0000000000000470
